<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38111704</article-id><article-id pub-id-type="pmc">PMC10726111</article-id><article-id pub-id-type="doi">10.3389/fendo.2023.1334519</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: The immune infiltrate as a paradigm model to study the biology and novel therapeutic approaches in sarcomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Recine</surname><given-names>Federica</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/907494"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Bongiovanni</surname><given-names>Alberto</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/678743"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Mercatali</surname><given-names>Laura</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Fausti</surname><given-names>Valentina</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/776001"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Ferraresi</surname><given-names>Virginia</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1970252"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>De Vita</surname><given-names>Alessandro</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/680140"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Medical Oncology Unit, Azienda Ospedaliera &#x0201c;San Giovanni Addolorata&#x0201d;</institution>, <addr-line>Roma</addr-line>, <country>Italy</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) &#x0201c;Dino Amadori&#x0201d;</institution>, <addr-line>Meldola</addr-line>, <country>Italy</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Sarcomas and Rare Tumors Unit, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute</institution>, <addr-line>Rome</addr-line>, <country>Italy</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) &#x0201c;Dino Amadori&#x0201d;</institution>, <addr-line>Meldola</addr-line>, <country>Italy</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited and Reviewed by: Claire Perks, University of Bristol, United Kingdom</p></fn><corresp id="fn001">*Correspondence: Alessandro De Vita, <email xlink:href="mailto:alessandro.devita@irst.emr.it">alessandro.devita@irst.emr.it</email>
</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><elocation-id>1334519</elocation-id><history><date date-type="received"><day>07</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Recine, Bongiovanni, Mercatali, Fausti, Ferraresi and De Vita</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Recine, Bongiovanni, Mercatali, Fausti, Ferraresi and De Vita</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/research-topics/41358" ext-link-type="uri">Editorial on the Research Topic <article-title>The immune infiltrate as a paradigm model to study the biology and novel therapeutic approaches in sarcomas</article-title>
</related-article><kwd-group><kwd>sarcomas</kwd><kwd>immunotherapy</kwd><kwd>tumor microenvironment</kwd><kwd>extracellular matrix</kwd><kwd>macrophages</kwd><kwd>T-cell infiltration</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="6"/><page-count count="2"/><word-count count="591"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Endocrinology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The tumor immune microenvironment (TiME) plays an essential role in tumor development as well as in tumor metastatization in a plethora of neoplasms, including soft tissue sarcoma (STS) and bone sarcomas (<xref rid="B1" ref-type="bibr">1</xref>). STS and bone sarcomas are a heterogeneous group of solid malignancies, encompassing more than 100 histological subtypes, with different biological and clinical behaviors, genomic backgrounds, and responses to treatments (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>).</p><p>TiME is a dynamic milieu of various types of elements, such as infiltrating immune cells, tumoral cells, and extracellular matrix, that have a potential role in the cancer growth process. Further understanding of the TiME mechanism is crucial for the development of new therapeutic agents, such as immunotherapy and its clinical application. Moreover, studying the role of the TiME in STS may contribute to improving the knowledge of the natural history and disease biology in this heterogenous group of rare mesenchymal tumors (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p><p>Articles published as part of the Research Topic &#x0201c;<italic>The Immune Infiltrate as a Paradigm Model to Study the Biology and Novel Therapeutic Approaches in Sarcomas</italic>&#x0201d; highlight the recent discoveries in this field, emphasizing the crucial role of the TiME in the etiopathogenesis of STS with the correlated clinical implications.</p><p>
<ext-link xlink:href="https://doi.org/10.3389/fimmu.2022.992266" ext-link-type="uri">Wu et&#x000a0;al.</ext-link> explored the correlation between angiogenesis and the TiME in osteosarcoma (OS) that underlies the network between the vessel state and immune infiltrate in this neoplasm. In the study, two subgroups of OS patients were identified according to the expression of angiogenesis-related genes (ARGs), and the vessel state and TiME of these groups were compared. The ARG score showed the correlation with angiogenesis and characterized the immune landscape of OS, leading to a risk score model and a prediction model of OS in the prognosis and response to immunotherapy.</p><p>In this context, <ext-link xlink:href="https://doi.org/10.3389/fonc.2023.1158857" ext-link-type="uri">Liao et&#x000a0;al.</ext-link> focused on the role of sulfatinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), in the management of OS patients. This agent showed dual activity as a multi-target TKI that inhibits proliferation in OS cells, by phosphorylating FGFR1 and downstream kinases, and modulates the TiME, increasing chemotherapy sensitivity.</p><p>Furthermore, in bone sarcomas, <ext-link xlink:href="https://doi.org/10.3389/fendo.2023.1187289" ext-link-type="uri">Weil and Loeb</ext-link> provided a detailed overview of the bone tumor microenvironment with a description of the various potential cancer mechanisms in this interplay. The authors emphasized the role of the crosstalk between sarcomas and the bone microenvironment, contributing to the control of tumor growth and cell extravasation and metastasis, as well as the implicated therapeutic potential options.</p><p>Another sarcoma histotype in which there is a relationship between systemic immune activation, angiogenesis, and tumor pathogenesis is Kaposi&#x02019;s sarcoma (KS). The authors reported a potential correlation between soluble markers of HIV-1-related immune activation and the level of growth factors in HHV-8 seropositive KS patients (<ext-link xlink:href="https://doi.org/10.3389/fimmu.2023.1216480" ext-link-type="uri">Nana et&#x000a0;al.</ext-link>).</p><p>The crucial role of TiME in tumorigenesis was also evaluated in epithelial tumors; in particular, in lung cancer, as described by (<ext-link xlink:href="https://doi.org/10.3389/fonc.2023.1064616" ext-link-type="uri">Zhao et&#x000a0;al.</ext-link>). The authors hypothesized a correlation between the changes in serum cytokine levels and the effectiveness of targeted immunotherapy in lung cancer and suggested immunological biomarkers as prognostic predictors for lung cancer.</p><p>In conclusion, the role of the TiME in the pathogenesis of tumors is still being studied due to the complexity and heterogeneity of this highly dynamic network of various elements. In this context, targeting the tumor microenvironment may be a promising therapeutic strategy for reducing tumor growth and metastasis and blocking therapeutic resistance.</p><sec sec-type="author-contributions" id="s1"><title>Author contributions</title><p>FR: Writing &#x02013; original draft. AB: Writing &#x02013; review &#x00026; editing. LM: Writing &#x02013; review &#x00026; editing. VFa: Writing &#x02013; review &#x00026; editing. VFe: Writing &#x02013; review &#x00026; editing. ADV: Writing &#x02013; review &#x00026; editing.</p></sec></body><back><sec sec-type="COI-statement" id="s3"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s4"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>RZ</given-names></name><name><surname>Meng</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The construction and analysis of tumor-infiltrating immune cell and ceRNA network in recurrent soft tissue sarcoma</article-title>. <source>Aging</source> (<year>2019</year>) <volume>11</volume>:<page-range>10116&#x02013;43</page-range>. doi: <pub-id pub-id-type="doi">10.18632/aging.102424</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Felisiak-Golabek</surname><given-names>A</given-names></name><name><surname>Lui&#x000f1;a Contreras</surname><given-names>A</given-names></name><name><surname>Glod</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Killian</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>New fusion sarcomas: histopathology and clinical significance of selected entities</article-title>. <source>Hum Pathol</source> (<year>2019</year>) <volume>86</volume>:<fpage>57</fpage>&#x02013;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.humpath.2018.12.006</pub-id>
<pub-id pub-id-type="pmid">30633925</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>WHO Classification of Tumours Editorial Board</collab></person-group>. <source>WHO Classification of Tumours of Soft Tissue and Bone</source>. <edition>5th ed</edition>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name> (<year>2020</year>).</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Recine</surname><given-names>F</given-names></name><name><surname>De Vita</surname><given-names>A</given-names></name><name><surname>Fausti</surname><given-names>V</given-names></name><name><surname>Pieri</surname><given-names>F</given-names></name><name><surname>Bongiovanni</surname><given-names>A</given-names></name><name><surname>Franchini</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>11</volume>:<elocation-id>740676</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2021.740676</pub-id>
<pub-id pub-id-type="pmid">35070960</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Vita</surname><given-names>A</given-names></name><name><surname>Recine</surname><given-names>F</given-names></name><name><surname>Miserocchi</surname><given-names>G</given-names></name><name><surname>Pieri</surname><given-names>F</given-names></name><name><surname>Spadazzi</surname><given-names>C</given-names></name><name><surname>Cocchi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2021</year>) <volume>40</volume>(<issue>1</issue>):<fpage>165</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13046-021-01963-1</pub-id>
<pub-id pub-id-type="pmid">33975637</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group>. <article-title>Strategies targeting tumor immune and stromal microenvironment and their clinical relevance</article-title>. <source>Adv Drug Delivery Rev</source> (<year>2022</year>) <volume>183</volume>:<fpage>114137</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.addr.2022.114137</pub-id>
</mixed-citation></ref></ref-list></back></article>
